Table 2.
Parameter | Current study (n = 130) | Iraq (n = 220) | Pakistan (n = 404) | Greece (n = 2000) | Taiwan (n = 5602) |
---|---|---|---|---|---|
Hb (g/dL) | 13.29 ± 1.5 | 13.76 ±1.46 | 14.99 ± 1.47 | 8.8 ±2.9 | 10.9 ± 1.4 |
PCV (%) | 44.8± 5.78 | 44.42 ± 4.74 | 45.65 ±4.83 | 25.9 ± 8.8 | 36.2 ± 4.3 |
RCC(x 1012/L) | 4.07± 0.55 | 4.0 ± 0.47 | 4.29 ± 0.44 | 2.46 ± 0.82 | 3.14 ± 0.41 |
MCV (fl) | 110.36± 11.88 | 111.56 ± 6.09 | 105.81 ± 6.24 | 105.0 ± 6.0 | 115.8 ± 6.8 |
MCH (pg) | 32.61± 4.13 | 34.41 ± 2.36 | 34.96 ±2.11 | 35.8 ± | 34.8 ± 1.8 |
MCHC (g/dL | 29.76 ± 1.64 | 30.93 ±1.90 | 32.47 ± 2.12 | 34.3 ±7.3 | 30.1 ±1.2 |
RDW | 19.75 ± 4.26 | 17.01 ± 1.63 | - | 12.1 ± 1.6 | - |
WBC(x 109/L) | 13.10 ± 5.20 | 10.12 ±2.8 | 13.61 ± 4.23 | 7.2 ± 3.4 | 10.0 ± 2.9 |
Platelets (x103/L) | 225.07 ±72.21 | 267.63 ±60.62 | 256.25 ±76.54 | 275 ± 125 | 217 ± 45 |